Open AccessThis article is
- freely available
Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors
UMR 7213 CNRS, Laboratoire de Biophotonique et Pharmacologie, Tumoral Signaling and Therapeutic Targets, Université de Strasbourg, Faculté de Pharmacie, 67401 Illkirch, France
* Author to whom correspondence should be addressed.
Received: 5 December 2012; in revised form: 9 January 2013 / Accepted: 11 January 2013 / Published: 15 January 2013
Abstract: Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.
Keywords: α5β1; integrin; fibronectin receptor; solid tumors; angiogenesis; antagonists
Citations to this Article
Cite This Article
MDPI and ACS Style
Schaffner, F.; Ray, A.M.; Dontenwill, M. Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers 2013, 5, 27-47.
Schaffner F, Ray AM, Dontenwill M. Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors. Cancers. 2013; 5(1):27-47.
Schaffner, Florence; Ray, Anne M.; Dontenwill, Monique. 2013. "Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors." Cancers 5, no. 1: 27-47.